Earnings Releases·Nov 10, 2026, 7:08 AM ET

Hemab Therapeutics — Third Quarter 2026 Earnings Summary

**Financial Results:** Net loss widened to $27.3 million ($0.58/share) for Q3 2026 from $17.1 million ($18.04/share) in Q3 2025, driven by a 69% increase in R&D expenses ($24.6M vs. $14.6M) and a 104% increase in G&A expenses ($5.1M vs. $2.5M); cash and marketable securities decreased to $430.2 million as of September 30, 2026, from $457.5 million in June 2026.
**Pipeline Progress:** Initiated the pivotal SOLARA Phase 3 trial for Sutacimig (HMB-001) in Glanzmann thrombasthenia; reported first Phase 2b data in Factor VII deficiency showing >50% prothrombin time reduction; dosed first participant in Phase 1 for HMB-003 (heavy menstrual bleeding); and presented HMB-002 data supporting potential monthly subcutaneous dosing.
**Strategic Updates:** Expanded board with commercial leader Keli Walbert; management confirmed cash resources are sufficient to fund operations through 2029; noted FDA recommendation for a randomized design in the SOLARA trial, acknowledging the risk of regulatory rejection for the proposed single-arm approach.
**Future Outlook:** Scheduled to present HMB-003 preclinical and FVIID Phase 2b data at the ASH Annual Meeting in December 2026, with HMB-002 data expected at the EAHAD Congress in February 2027 and initial HMB-003 clinical data anticipated in mid-2027.